RAPT Therapeutics (RAPT) AI Stock Analysis

• Market Cap: $864.58M
• Dividend Yield: N/A
• Average Volume (3M): 380.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: N/A
• EPS Growth: 50.23%
• Country: US
• Employees: 67
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 27,710,870
• 10 Day Avg. Volume: 284,076
• 30 Day Avg. Volume: 380,131
• PEG Ratio: -0.86
• Price to Book (P/B): 2.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.18
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.30K
• Enterprise Value/Ebitda: -6.11
• 1Y Price Target: $67.78
• Price Target Upside: 117.24% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $38.00 ▲(21.79% Upside)

Score reflects a strong technical uptrend and meaningful positive corporate events (extended funding runway and positive Phase 2 data), partially offset by weak financial performance driven by $0 revenue, sizable ongoing losses, and heavy negative free cash flow. Valuation provides limited support given the negative P/E and no dividend yield data.

Positive Factors

Strong Equity Position

A strong equity position with low leverage provides financial stability and flexibility, supporting long-term strategic initiatives and potential growth opportunities.

Proprietary Drug Discovery

The proprietary drug discovery platform is a competitive advantage, enabling RAPT to develop unique therapies that can address unmet medical needs, potentially leading to successful commercialization.

Board Restructuring

Streamlining the board can lead to more efficient decision-making processes, potentially enhancing strategic focus and aligning leadership with the company's long-term goals.

Negative Factors

Inability to Generate Revenue

The lack of revenue generation is a critical concern, as it limits the company's ability to sustain operations without external funding, posing a risk to long-term viability.

Consistent Operating Losses

Ongoing operating losses indicate challenges in achieving profitability, which can strain financial resources and hinder the company's ability to invest in growth and development.

Negative Cash Flow

Negative cash flow from operations highlights difficulties in generating sufficient cash internally, increasing reliance on external financing and impacting financial sustainability.

RAPT Therapeutics Business Overview & Revenue Model

Company Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

RAPT Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies, as well as government grants and funding for its research initiatives. The company may also license its proprietary technology and intellectual property to other firms, providing another revenue stream. As RAPT advances its product candidates through clinical trials and towards potential commercialization, it anticipates generating revenue from the sale of its therapies upon obtaining necessary regulatory approvals.

RAPT Therapeutics Financial Statement Overview

Summary

RAPT Therapeutics faces significant challenges, primarily due to its inability to generate revenue and consistent operating losses. While the balance sheet shows a strong equity base and low leverage, the company's cash flow and income statement highlight sustainability concerns.

Income Statement

RAPT Therapeutics has consistently reported negative net income and EBIT over the past years, indicating ongoing operational challenges. The company has not generated any revenue in recent years, which is a concern for sustainability. The lack of revenue and consistent losses contribute to a low score for the income statement.

Balance Sheet

The balance sheet shows a relatively strong equity position with a low debt-to-equity ratio, indicating conservative leverage. However, the lack of revenue generation poses a risk to the sustainability of the company's financial health. The equity ratio is high, showing a solid capital structure, but the ongoing losses are a concern.

Cash Flow

The company has consistently reported negative operating and free cash flows, pointing to challenges in generating cash from operations. The reliance on financing activities to support cash flow needs is notable. Despite this, the company has maintained a healthy cash position, mitigating some risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	1.53M	3.81M	5.04M
Gross Profit	-200.00K	0.00	0.00	1.53M	3.81M	5.04M
EBITDA	-108.01M	-134.90M	-125.85M	-84.75M	-68.21M	-52.09M
Net Income	-105.64M	-129.87M	-116.80M	-83.84M	-69.20M	-52.89M
Balance Sheet
Total Assets	165.74M	240.32M	173.33M	266.21M	198.64M	118.97M
Cash, Cash Equivalents and Short-Term Investments	157.34M	231.06M	158.86M	249.07M	189.65M	111.51M
Total Debt	2.60M	4.49M	6.91M	8.99M	0.00	0.00
Total Liabilities	13.76M	50.42M	26.29M	21.04M	12.26M	14.79M
Stockholders Equity	151.98M	189.90M	147.03M	245.17M	186.38M	104.18M
Cash Flow
Free Cash Flow	-86.66M	-83.42M	-98.17M	-71.62M	-61.78M	-40.89M
Operating Cash Flow	-86.58M	-83.30M	-97.05M	-70.77M	-61.03M	-40.49M
Investing Cash Flow	-56.70M	52.70M	104.13M	-45.49M	-81.35M	-87.44M
Financing Cash Flow	143.31M	152.85M	1.45M	131.18M	141.48M	75.46M

RAPT Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 31.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPT, the sentiment is Negative. The current price of 31.2 is below the 20-day moving average (MA) of 33.97, below the 50-day MA of 31.77, and above the 200-day MA of 17.55, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 44.84 is Neutral, neither overbought nor oversold. The STOCH value of 24.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RAPT.

RAPT Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAPT	60 Neutral	$864.58M	-2.82	-85.37%	―	―	50.23%
DBVT	60 Neutral	$706.33M	-3.24	-234.58%	―	―	1.29%
ENGN	55 Neutral	$569.37M	-3.70	-53.28%	―	―	-52.86%
AUTL	54 Neutral	$508.33M	-2.26	-60.52%	―	407.86%	30.35%
LXEO	53 Neutral	$691.19M	―	-80.69%	―	―	4.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NGNE	50 Neutral	$289.35M	-4.22	-42.25%	―	-100.00%	1.47%

RAPT Therapeutics Corporate Events

RAPT Therapeutics Announces CMO Departure

On November 24, 2025, RAPT Therapeutics announced that Chief Medical Officer Dr. William Ho will leave the company on December 31, 2025. Dr. Ho will receive severance benefits and healthcare coverage, and will continue as a strategic consultant with the company until December 31, 2026, allowing him to retain equity award vesting rights.

The most recent analyst rating on (RAPT) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.

RAPT Therapeutics Announces Major Public Stock Offering

On October 21, 2025, RAPT Therapeutics, Inc. announced an underwritten public offering of 8,333,334 shares of its common stock at $30.00 per share, with an option for underwriters to purchase an additional 1,250,000 shares. The company expects to raise approximately $234.4 million, potentially extending to $269.7 million if the option is fully exercised, which will fund operations into 2028. The offering is expected to close on October 23, 2025, subject to customary conditions, and reflects RAPT’s strategic move to secure capital for its ongoing and future projects.

The most recent analyst rating on (RAPT) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.

RAPT Therapeutics Reports Positive Phase 2 Trial Results

On October 20, 2025, RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Co., Ltd. announced positive results from a phase 2 trial of RPT904 for chronic spontaneous urticaria. The trial showed that RPT904, administered at 8-week and 12-week intervals, demonstrated comparable efficacy and safety to omalizumab, a standard treatment dosed every 4 weeks. These findings suggest RPT904’s potential as a more convenient treatment option, prompting plans to advance to phase 3 trials and discussions with regulatory authorities. The trial involved 137 patients and highlighted RPT904’s sustained efficacy and tolerability, with no serious adverse events reported.

The most recent analyst rating on (RAPT) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.